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Upper gastrointestinal bleeding (UGIB) and myocar-
dial ischemia/infarction may occur simultaneously
because massive UGIB compromises myocardial per-
fusion and reflex tachycardia increases myocardial
oxygen consumption. Many studies were conducted
to evaluate the causes and consequences of UGIB
after acute myocardial infarction (AMI) and have found
that decreased gastrointestinal blood flow and anti-
platelet or anticoagulation therapy during AMI are
two of the major causes of bleeding [1]. Myocardial
injury after UGIB is frequently ignored because the
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The aims of this study were to: (1) evaluate the epidemiology of simultaneous upper gastrointesti-
nal bleeding (UGIB) and myocardial injury using parameters including troponin I (TnI); and 
(2) investigate the predictive risk factors of this syndrome. One hundred and fifty-five patients (101
men, 54 women; mean age, 64.7 ± 10.4 years; range, 38–94 years) at the emergency department
(ED) with the major diagnosis of UGIB were included. They underwent serial electrocardiography
(ECG) and cardiac enzyme follow-up. Emergent gastroendoscopy was performed within 24 hours
in most patients except for those who refused or were contraindicated. Mild myocardial injury
was defined as the presence of any of the following: typical ST-T change on ECG, elevated crea-
tine kinase-MB (CK-MB) > 12 U/L, or TnI > 0.2 ng/dL. Moderate myocardial injury was defined as
the presence of any two of the previously mentioned conditions. In total, 51 (32.9%) and 12 (7.74%)
patients developed mild and moderate myocardial injuries, respectively. Myocardial injury was
more common among patients with variceal bleeding (20/25=80.0%) than those with ulcer bleeding
(23/112 = 20.5%). It could partially be attributed to a higher baseline TnI level in cirrhotic patients.
After adjusting for significant risk factors revealed by the univariate analysis, UGIB patients with
a history of liver cirrhosis and more than three cardiac risk factors comprised a high-risk group for
simultaneously developing myocardial injury. Other factors including age, gender, the color of
nasogastric tube irrigation fluid, history of nonsteroidal anti-inflammatory drug use, vasopressin
or terlipressin administration, vital signs, and creatinine recorded at the ED were not significant
predictors. Those who developed myocardial injury had a longer hospital stay (mean duration,
8.73±6.94 vs. 6.34±2.66 days; p=0.03) and required transfusion of more units of packed erythrocytes.
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signs and symptoms may be overshadowed by severe
UGIB [2]. Several studies showed that this process is
common, especially in critically ill patients [2–5]. Except
for those with more cardiac risk factors and more
severe anemia, there is no mutual agreement about
other risk factors in this group. High-output heart
failure has been noticed in cirrhotic patients and 
this syndrome is termed cirrhotic cardiomyopathy.
Ventricular hyporesponsiveness is revealed when 
cirrhotic patients are challenged by pharmacologic 
or physiologic stress [6]. In addition, hemodynamic
instability is often noticed in patients with liver cir-
rhosis and variceal bleeding [7]. This could potenti-
ate (subclinical) heart failure and myocardial injury.
Some medications used to treat bleeding varices, in-
cluding terlipressin and vasopressin, have the poten-
tial for aggravating myocardial ischemia because of
their coronary artery vasoconstricting effect [8,9]. How-
ever, their impact on myocardial injury during UGIB
is generally not recognized.
Troponin I (TnI), which is more frequently used 
in recent years, is a more rapidly-rising and specific
marker and outcome predictor during AMI [10]. It
was shown to be a better biologic marker to detect
occult myocardial injury during UGIB [5]. Pateron 
et al showed a frequent elevated TnI (32%) above the
lower detection limit in patients with cirrhosis and
indicated that it was associated with subclinical left
ventricular myocardial injury [11]. The aims of this
study were to: (1) evaluate the epidemiology of
simultaneous UGIB and myocardial injury using
parameters including TnI; and (2) determine the pos-
sible risk factors in patients who develop simultaneous
myocardial injury.
PATIENTS AND METHODS
Patients
Patients at the emergency department (ED) of
Kaohsiung Medical University Hospital during the
period from July to December 2004 with the chief
complaint of tarry stool passage or blood vomitus
were diagnosed with UGIB. This hospital is a tertiary
referral medical center in the Kaohsiung metropoli-
tan area of southern Taiwan. All were admitted to the
gastrointestinal (GI) ward after stabilization. All UGIB
subjects older than 35 years were included. Because
myocardial injury is less common in younger and
previously healthy patients with minor bleeding, we
excluded those with the presence of the following: 
(1) younger than 35 years; (2) having less than three
cardiac risk factors; (3) initial systolic blood pressure
(BP) >100mmHg; and (4) initial hemoglobin (Hb)
>12g/dL. Subjects underwent standardized treatment
according to current guidelines [7,12]. Most of them
underwent emergent gastroendoscopy within 24 hours,
except for those who refused or were contraindicated
(irritable patients or with arrhythmia and severe
shock). During gastroendoscopic examination, hemo-
static strategies were employed if peptic ulcers with
exposure vessels or varices with signs of recent bleed-
ing were diagnosed.
Risk factors and outcome
Electrocardiography (ECG) was done on arrival at the
ED and 4 hours later. Cardiac enzymes, including
creatine kinase (CK), CK-MB, and TnI (Beckman
Coulter Ireland, Inc., Fullerton, CA, USA) were checked
every 12 hours for three times after admission. The
presence of liver cirrhosis was previously diagnosed in
our hospital when a typical change in abdominal ultra-
sound in addition to a long-standing hepatitis history
or evidence of hepatic decompensation (elevated biliru-
bin level, prolonged prothrombin time, presence of
varices in gastroendoscopic examination, encephalopa-
thy) were identified. We used the five traditional car-
diac risk factors (diabetes, hypertension, first-degree
relatives with premature MI [male relatives <45 years,
female relatives < 55 years], hypercholesterolemia,
smoking) and also included other commonly associ-
ated risk factors (age, male gender, obesity). Previous
UGIB history, underlying malignancy and drug use
including aspirin, coumadin, nonsteroidal anti-
inflammatory drug (NSAID) and steroid, and history
of smoking and alcoholic beverage drinking were
evaluated using a standardized questionnaire.
In our study, mild myocardial injury was defined
as the presence of any of the following: serial ST-T
deviation in two consecutive leads on ECG; elevated
CK-MB>12 U/L or TnI>0.2ng/dL (normal, <0.02ng/
dL) [13,14]. Moderate myocardial injury was defined
as the presence of any two of the previously mentioned
conditions. Recurrent bleeding was diagnosed and
recorded if patients had an increased amount of tarry
stool with hemodynamic instability (tachycardia or
hypotension) and decreased Hb measurement within
3 days of initial therapy. Such patients underwent
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gastroendoscopy for revision and hemostasis. Intra-
venous medication used to control bleeding (omepra-
zole, vasopressin, terlipressin, or somatostatin), total
amount of packed erythrocyte transfusion, length of
hospital stay, intensive care unit (ICU) stay and compli-
cations including severe infection, respiratory failure,
acute renal failure, were also recorded and analyzed.
Statistical analysis
The χ2 test or Fisher’s exact test was used to examine
the presence of mild or moderate myocardial injury
by the distribution of general characteristics. Logistic
regression was used to investigate the relationship
between mild or moderate myocardial injury and other
potential predictors that were significant in the uni-
variate analysis. Data were analyzed using the SAS
statistical package (SAS Institute Inc., Cary, NC, USA),
and the significant two-sided p value was 0.05.
RESULTS
Prevalence of simultaneous UGIB and
myocardial injury
One hundred and eighty-six patients diagnosed with
UGIB were admitted to the GI ward via the ED.
Twenty-one of them were excluded according to the
exclusion criteria and 10 refused to participate in the
study. Of the 155 patients (101 men, 54 women; mean
age, 64.7±10.4 years; range, 38–94 years) enrolled in this
study, 152 underwent emergent endoscopy. The bleed-
ing sources were from peptic ulcer (esophageal, gastric,
or duodenal ulcer) in 112 patients, from varices in 25
and from other lesions (esophagitis, acute gastric muco-
sal lesion, or gastric erosion) in 15 patients (Table 1).
Sixteen (10.6%) had ST-T deviation on ECG. Thirty-nine
(25.2%) and 13 (8.4%) had elevated CK-MB and TnI
above the upper limit, respectively. In total, 51 (32.9%)
had abnormality in any of the three and were defined
as developing mild myocardial injury. Twelve (7.74%)
patients had simultaneous moderate myocardial injury
and two of them were transferred to the ICU due to
overt MI. Catecholamines were not used in any of them.
Risk factors for UGIB patients who
developed mild or moderate myocardial
injury
Thirty patients (19.4%) had a history of NSAID expo-
sure and six of them were taking aspirin. Among the
155 patients, 31 (20.0%) had underlying liver cirrho-
sis. Fourteen of the 22 (66.5%) subjects diagnosed with
variceal bleeding received intravenous omeprazole
and terlipressin or vasopressin simultaneously in the
first 2 days. Somatostatin was used in the remaining
eight patients. Only one of the 130 cases with non-
variceal bleeding received such vasoactive agents in
addition to intravenous omeprazole. Myocardial injury
was more common among patients with variceal bleed-
ing (20/25 = 80.0%) than those with ulcer bleeding
(23/112 = 20.5%). However, it was not related to vaso-
pressin or terlipressin use. Mean TnI level was slightly
higher among the 112 ulcer bleeding cases (0.11 ±
0.41 ng/dL) than the 25 variceal bleeding cases (0.80 ±
3.73 ng/dL; p = 0.054). In the ulcer bleeding group,
seven patients (6.25%) had underlying cirrhosis. After
adjusting for age, gender, and other potential con-
founders revealed by univariate analysis, the presence
of underlying cirrhosis (p = 0.01) and more cardiac risk
factors (p = 0.007) were associated with the develop-
ment of mild myocardial injury. The mean age of the
104 UGIB patients without myocardial injury was
65.0 ± 12.2 years (range, 36–94 years), while that of the
51 patients with myocardial injury was 64.4±13.2 years
(range, 39–85 years; p = 0.79). The mean lowest hema-
tocrit (Hct) level was 26.52 ± 7.58% in the 104 UGIB
controls and 24.28 ± 5.57% in the 51 patients with
simultaneous myocardial injury.
Univariate analysis revealed that liver cirrhosis,
pitressin or terlipressin use, fresh color during naso-
gastric (NG) tube irrigation, more cardiac risk factors
(> three items), and a lowest Hct ≤ 25% are risk factors
in UGIB patients for developing mild myocardial
injury (Table 1). After adjusting for those potential con-
founders, liver cirrhosis (adjusted odds ratio [aOR] =
7.68, 95% confidence interval [CI] = 2.78–21.20, p <
0.0001) and the presence of more than three cardiac
risk factors (aOR = 3.38, 95% CI = 1.35–8.46, p = 0.009)
were still significant predictors (Table 2). The signi-
ficant predictors in UGIB patients who developed
moderate myocardial injury were the same as the ones
for mild myocardial injury by using univariate analy-
sis (data not shown). After adjusting for age, sex, and
other significant predictors in univariate analysis,
liver cirrhosis and more than three cardiac risk 
factors remained significant risk factors (Table 2).
Together, the mean BP and pulse rate on arrival, initial
Hb and blood urea nitrogen (BUN)/creatinine (Cr)
ratio were not significant predictors of the presence
UGI bleeding with simultaneous myocardial injury
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of subsequent myocardial injury. Age, gender, dia-
betes mellitus, hypertension, renal function abnor-
mality (Cr > 1.6 mg/dL), history of malignancy and
use of painkillers were not found to be significant
risk factors.
Outcome
One patient was discharged against advice on the 1st
day and was excluded when analyzing the adverse
outcome. As shown in Table 3, it was found that
those who developed mild myocardial injury had a
Table 1. Distribution of general characteristics among 155 upper gastrointestinal bleeding cases dichotomized by the
presence of mild myocardial injury
Mild myocardial injury
Variables Case no.
Present (n = 51), n (%) Absent (n = 104), n (%)
p
Gender 0.32
Male 101 36 (70.6) 65 (62.5)
Female 54 15 (29.4) 39 (37.5)
Age, yr 0.27
≤ 55 40 16 (31.4) 24 (23.1)
> 55 115 35 (68.6) 80 (76.9)
Mean BP on arrival (mmHg) 0.14
≤ 70 80 22 (43.1) 58 (55.8)
> 70 75 29 (56.2) 46 (44.2)
Cardiac risk factors 0.02
≤ 3 94 24 (47.1) 70 (67.3)
> 3 61 27 (52.9) 34 (32.7)
Liver cirrhosis < 0.0001
Absent 124 30 (58.8) 94 (90.4)
Present 31 21 (41.2) 10 (9.6)
Vasopressin or terlipressin use 0.015
Absent 141 42 (82.4) 99 (95.2)
Present 14 9 (17.6) 5 (4.8)
NG color* 0.008
Fresh 44 20 (39.2) 24 (23.1)
Not fresh 91 21 (41.2) 70 (67.3)
Missing 20 10 (19.6) 10 (9.6)
Initial Cr (mg/dL) 0.73
≤ 1.6 127 41 (80.4) 86 (82.7)
> 1.6 28 10 (19.6) 18 (17.3)
Lowest Hct (%) 0.09
≤ 25 73 29 (56.9) 44 (42.3)
> 25 82 22 (43.1) 60 (56.7)
History of NSAID use 0.34
Absent 125 39 (76.5) 86 (82.7)
Present 30 12 (23.5) 18 (17.3)
Cause of bleeding < 0.0001
Peptic ulcer† 112 23 (45.1) 89 (85.6)
Varices 25 20 (39.2) 5 (4.8)
Others‡ 15 5 (9.8) 10 (9.6)
Missing 3 3 (5.9) 0
*The color of the fluid during nasogastric tube irrigation; †including esophageal, gastric, and duodenal ulcers; ‡including esophagitis,
acute gastric mucosal lesion, and gastric erosion. BP = blood pressure; NG = nasogastric; Cr = creatinine; Hct = hematocrit; NSAID =
nonsteroidal anti-inflammatory drug.
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longer hospital stay (mean duration = 8.9 ± 6.91 vs.
6.31 ± 2.65 days, p = 0.013) and required more packed
erythrocyte transfusion (5.94 ± 4.07 vs. 4.07 ± 3.94, p =
0.007) than those who did not. A higher rebleeding rate
(eight cases, 5.19%) was also seen in those with mod-
erate myocardial injury than those without (25% vs.
3.5%, p = 0.01). In those who had recurrent UGIB, five
were from benign gastric ulcers, two were from duo-
denal ulcers, and one was from esophageal varices.
None of them had a history of NSAID use. Four
patients died; one and two of them had mild and
moderate myocardial injury, respectively. One of them
had rebleeding.
DISCUSSION
In our study, the prevalence of simultaneous UGIB and
moderate myocardial injury (7.74%) is similar to previ-
ous studies (0.94–14%) [2–4]. One of the explanations
Table 2. Distribution of variables and potential confounders among the cases with mild or moderate myocardial injury
and 104 upper gastrointestinal bleeding controls without myocardial injury
Control 
Mild myocardial ischemia (n = 51) Moderate myocardial injury (n = 12)
n (%) aOR* p n (%) aOR* p
Variables
(n = 104), n (%)
(95% CI) (95% CI)
Gender 0.93 0.97
Male 65 (62.5) 36 (70.6) 1.00 8 (75.0) 1.00
Female 39 (37.5) 15 (29.4) 0.92 4 (25.0) 0.96
(0.34–2.50) (0.16–5.80)
Age, yr 0.93 0.18
≤ 55 24 (23.1) 16 (31.4) 1.00 3 (25.0) 1.00
> 55 80 (76.9) 35 (68.6) 1.00 9 (75.0) 1.05
(0.97–1.03) (0.98–1.12)
CAD risk factors 0.009 0.02
≤ 3 72 (69.2) 24 (47.1) 1.00 4 (25.0) 1.00
> 3 34 (30.8) 27 (52.9) 3.38 8 (75.0) 8.52
(1.35–8.46) (1.37–53.09)
Liver cirrhosis < 0.0001 0.01
Absent 94 (90.4) 30 (58.8) 1.00 6 (50.0) 1.00
Present 10 (9.6) 21 (41.2) 7.68 6 (50.0) 11.67
(2.78–21.20) (1.66–82.69)
Vasopressin or 0.35 0.21
terlipressin use
Absent 99 (95.2) 42 (82.4) 1.00 8 (66.7) 1.00
Present 5 (4.8) 9 (17.6) 1.96 4 (33.3) 5.74
(0.48–8.07) (0.49–28.74)
NG color†
Fresh 24 (22.1) 20 (39.2) 1.00 7 (58.3) 1.00
Not fresh 70 (67.3) 21 (41.2) 0.65 0.37 3 (25.0) 0.36 0.26
(0.26–1.66) (0.06–2.14)
Missing 10 (9.6) 10 (19.6) 2.32 0.18 2 (16.7) 3.05 0.32
(0.68–7.89) (0.34–27.82)
Lowest Hct (%) 0.15 0.86
≤ 25 44 (42.3) 29 (56.9) 1.00 7 (58.3) 1.00
> 25 60 (57.7) 22 (43.1) 0.56 5 (41.7) 0.87
(0.25–1.24) (0.20–3.89)
*aOR, after adjusting for age (≤ 55 vs. > 55 yr), gender (male vs. female), CAD risk factors (≤ 3 vs. > 3 items), NG color (fresh or not), low-
est Hct (≤ 25% vs. > 25%), the presence of liver cirrhosis or vasopressin use; †the color of the fluid during nasogastric tube irrigation.
aOR = adjusted odds ratio; CI = confidence interval; CAD = coronary artery disease; NG = nasogastric; Hct = hematocrit.
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for the variety in prevalence is that different parame-
ters were used to define myocardial injury in those
without chest complaints. In earlier studies, ECG, CK,
and CK-MB but not TnI were used to define myocar-
dial injury, and some of them were retrospective
studies in which the prevalence might be underesti-
mated. Recent reports showed that TnI is a more sen-
sitive and specific marker for myocardial necrosis or
strain [15]. However, elevation of TnI has been reported
in various conditions including pulmonary embolism
[16], major trauma [17], septic shock [18,19], and
chronic renal insufficiency [20]. It is not always syn-
onymous with infarction or ischemia. The level 
of significance of TnI elevation depends on the assay
cut-off value. In a study of 227 UGIB patients, 12%
were found to develop myocardial injury defined as
an elevation of TnI (RxL Dimension, Dade Behring,
Milan, Italy) above 0.15 ng/dL. The authors also
showed that among the potential risk factors such as
ECG change, initial BP, and history of coronary artery
disease (CAD), only minimum Hb was found to be a
significant predictor. Liver cirrhosis and mild renal
dysfunction (Cr, 1.5–2.0 mg/dL) were not significantly
associated with an elevated TnI [5]. Our study differed
in that an integration of biomarkers (TnI and CK-MB)
and ECG were used to define myocardial injury. The
identified significant predictors were consistent using
either one or two abnormalities as an indicator of
myocardial injury. A recent report suggested that such
an integration will help identify false-positive acute
coronary syndrome patients in the ED [21].
Our study found that cirrhotic patients were prob-
ably among the high-risk groups to develop myocar-
dial injury during UGIB. Vasopressin and terlipressin
are commonly used to treat bleeding varices in cirrhotic
patients and might cause coronary vasocontracting
side effects [8,9]. In contrast, there is no evidence to
suggest that somatostatin has coronary side effects.
After adjusting for confounders including the use of
those two drugs, cirrhosis was still shown to be a sig-
nificant risk factor. However, vasopressin or terli-
pressin use was not an independent risk factor for
developing myocardial injury. A study investigating
32 patients with liver cirrhosis showed that 10 (32%)
had slightly elevated TnI (range, 0.06–0.25ng/dL) [11].
Echocardiography was done and the authors sug-
gested that elevated TnI was associated with subclin-
ical left ventricular myocardial damage. One of our
study’s limitations is that we did not check the base-
line CK-MB and TnI levels. The finding of a higher
prevalence of myocardial injury among the variceal
bleeding group (80.0%) than among the ulcer bleeding
group (20.5%) could partially be attributed to a higher
baseline CK-MB or TnI level in patients with liver cir-
rhosis. However, in the ulcer bleeding group, fewer
patients (6.25%) had underlying cirrhosis, and we
still found that those with more CAD risk factors and
liver cirrhosis were in the high-risk group to develop
Table 3. Comparison of the outcome among the 154 upper gastrointestinal bleeding cases according to presence of
clue to myocardial injury*
Mild myocardial injury Moderate myocardial injury
Present Absent
p
Present Absent
p
(n = 50), n (%) (n = 104), n (%) (n = 12), n (%) (n = 142), n (%)
Hospital stay (d)†
Mean ± SD 8.9 ± 6.91 6.31 ± 2.65 0.013 12.33 ± 10.82 6.72 ± 3.42 0.10
PRBC transfusion (units)†
Mean ± SD 5.94 ± 4.07 4.07 ± 3.94 0.007 8.25 ± 5.32 4.39 ± 3.81 0.001
In-hospital complications‡§
Present 20 (40.0) 39 (37.5) 0.77 6 (50) 53 (37.32) 0.39
Absent 30 (60.0) 65 (62.5) 6 (50) 89 (62.68)
Rebleeding¶
Present 4 (8.0) 4 (3.85) 0.28 3 (25) 5 (3.52) 0.001
Absent 46 (92.0) 100 (96.15) 9 (75) 137 (96.48)
*One patient was discharged against advice on the 1st day and was excluded; †Student’s t test; ‡in-hospital complications included
acute renal failure, respiratory failure, or severe infection; §χ2 test; ¶Fisher’s exact test. SD = standard deviation; PRBC = packed red
blood cells.
myocardial injury. In addition, we used a higher TnI
level (0.2ng/dL) to define the development of myocar-
dial injury. Thus, other factors exist in addition to a
higher baseline TnI to explain why cirrhosis is a risk
factor of this syndrome. Although the effect of liver
cirrhosis on coronary microcirculation is not clear, the
cirrhotic heart develops a series of structural and func-
tional abnormalities consisting of diastolic dysfunction
and reduced myocardial reactivity during exercise
[22,23]. These provide an explanation as to why cir-
rhotic patients are more susceptible to myocardial
injury during UGIB and physicians should pay more
attention to such patients.
The development of concurrent myocardial injury
is associated with the amount and acuteness of blood
loss, which is difficult to estimate precisely. It was
reported that severe postpartum hemorrhage with
hypovolemic shock is highly related to concurrent
myocardial injury indicated by elevated TnI and ECG
change, especially in those treated with catecholamine
[24]. The amount of blood loss could be estimated by
the presence of hypotension, tachycardia, orthostatic
hypotension, and azotemia (BUN>40mg/dL or BUN/
Cr > 20). Because it takes hours to achieve full com-
pensation, the initial Hct or Hb measurement is not
considered to be a good indicator of severity during
acute blood loss. Frequent monitoring and careful
fluid resuscitation are recommended. There is still con-
troversy regarding the lowest Hb concentration that
can safely be tolerated. One report showed that rever-
sible AMI after blood transfusion was found in eld-
erly patients with massive GIB (mean Hct elevated
from 28.9% to 47.7%) [25]. In another study intro-
ducing isovolemic reduction of Hb concentration in
55 healthy adults, transient, reversible ST-segment
depression occurred in three asymptomatic subjects
when it reduced to 5–7 g/dL [26]. In our study, initial
and minimum Hct levels (≤ 25% vs. > 25%) were not
significant predictors for UGIB patients to develop
myocardial injury. However, it is still important to
consider the necessity of adequate blood transfusion
before performing gastroendoscopy, which further
increases heart load.
Only eight of the 154 cases (5.19%) had recurrent
UGIB and none of them had a history of NSAID use.
Recurrent bleeding occurred more often in patients
who developed moderate myocardial injury (25% vs.
3.52%, p = 0.01), in whom antiplatelet or anticoagula-
tion drugs were contraindicated. Three of the four
cases of mortality were from the group who devel-
oped myocardial injury and one of them had recur-
rent UGIB. It follows that major complications often
occur simultaneously, and treatment of rebleeding or
MI should be coupled together. Those who devel-
oped moderate myocardial injury (n=12) tended to
have a longer hospital stay than those without. How-
ever, the difference was not significant and could be
attributed to a smaller case number in this group.
Another limitation of this study is that we did not
exclude patients who had CK-MB or TnI above nor-
mal range on arrival, so it is difficult to tell if myo-
cardial injury develops before, concurrent with, or
after UGIB.
In conclusion, UGIB patients with a history of
liver cirrhosis and more than three cardiac risk fac-
tors had a high risk of simultaneously developing
myocardial injury. More adverse outcomes were
found in those patients. Monitoring ECG and cardiac
enzymes, including TnI, are recommended in high-
risk patients, even if no chest complaints are present.
Further studies are necessary to investigate the exact
mechanisms by which liver cirrhosis precipitates
myocardial injury during UGIB.
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